Skip to main content
Home > Week in Review > Deals

Chronological Index of : Deals

 Current Issue
  • Lumara Health, AMAG Pharmaceuticals deal

    Lumara Health Inc., Chesterfield, Mo. AMAG Pharmaceuticals Inc. (NASDAQ:AMAG), Lexington, Mass. Business: Genitourinary AMAG completed its acquisition of Lumara Health for $600 million in upfront cash, up to $350 …

    Published on 11/24/2014
  • Mayo Clinic, Second Genome deal

    Mayo Clinic, Rochester, Minn. Second Genome Inc., San Francisco, Calif. Business: Autoimmune, Cancer, Endocrine/Metabolic Second Genome partnered with the Mayo Clinic Center for Individualized Medicine to identify …

    Published on 11/24/2014
  • Medical Prognosis Institute, Alion deal

    Medical Prognosis Institute A/S, Horsholm, Denmark Alion Pharmaceuticals Inc., San Bruno, Calif. Business: Cancer MPI will use its drug response predictor (DRP) to identify a predictive biomarker for selecting cancer …

    Published on 11/24/2014
  • Medtronic, Capricor Therapeutics deal

    Medtronic Inc. (NYSE:MDT), Minneapolis, Minn. Capricor Therapeutics Inc. (OTCQB:CAPR), Beverly Hills, Calif. Business: Cardiovascular Capricor purchased Medtronics patent related to the formulation and pump delivery of …

    Published on 11/24/2014
  • Melior, Bukwang deal

    Melior Discovery Inc., Exton, Pa. Bukwang Pharmaceutical Co. Ltd., Seoul, South Korea Business: Endocrine/Metabolic Melior received the first milestone payment under a 2013 deal granting Bukwang exclusive rights to …

    Published on 11/24/2014
  • Merck KGaA, Institute of Cancer Research, Wellcome Trust deal

    Merck KGaA (Xetra:MRK), Darmstadt, Germany The Institute of Cancer Research, London, U.K. Wellcome Trust, London, U.K. Business: Cancer Mercks Merck Serono S.A. unit, The Institute of Cancer Research and the Wellcome …

    Published on 11/24/2014
  • Merck KGaA, Pfizer deal

    Merck KGaA (Xetra:MRK), Darmstadt, Germany Pfizer Inc. (NYSE:PFE), New York, N.ZZZ. Business: Cancer Pfizer partnered with Merck to co-develop and co-commercialize Mercks MSB0010718C as a single agent and in combination…

    Published on 11/24/2014
  • NeuroSearch, Saniona deal

    NeuroSearch A/S (CSE:NEUR), Ballerup, Denmark Saniona AB (AktieTorget:SANION), Ballerup, Denmark Business: Neurology, Endocrine/Metabolic NeuroSearch transferred to Saniona rights to NS2359 and tesofensine (NS2330). …

    Published on 11/24/2014
  • Nicox, OptiMed deal

    Nicox S.A. (Euronext:COX), Sophia Antipolis, France OptiMed Pty. Ltd., Lane Cove, Australia Business: Diagnostic, Ophthalmic Nicox granted OptiMed exclusive rights in Australia and New Zealand to distribute AdenoPlus …

    Published on 11/24/2014
  • Novartis, Womens Choice Pharmaceuticals LLC deal

    Novartis AG (NYSE:NVS;SIX:NOVN), Basel, Switzerland Womens Choice Pharmaceuticals LLC, Gilbert, Ariz. Business: Infectious Novartis Sandoz Inc. generics unit sublicensed promotional rights to genital wart treatment …

    Published on 11/24/2014
  • Oxford BioMedica, Novartis deal

    Oxford BioMedica plc (LSE:OXB), Oxford, U.K. Novartis AG (NYSE:NVS;SIX:NOVN), Basel, Switzerland Business: Cancer, Gene/Cell therapy, Drug delivery The companies expanded May 2013 deal under which Oxford BioMedica is …

    Published on 11/24/2014
  • Pharming, Swedish Orphan Biovitrum deal

    Pharming Group N.V. (Euronext:PHARM), Leiden, the Netherlands Swedish Orphan Biovitrum AB (SSE:SOBI), Stockholm, Sweden Business: Cardiovascular The companies added seven countries to an amended 2010 deal granting …

    Published on 11/24/2014
  • Rottapharm Madaus, Meda deal

    Rottapharm Madaus Group, Monza, Italy Meda AB (SSE:MEDAA), Solna, Sweden Business: Pharmaceuticals Meda completed its acquisition of Rottapharm for SEK15.3 billion ($2.1 billion) in cash and 30 million shares valued …

    Published on 11/24/2014
  • Sanofi, Ferring deal

    Sanofi (Euronext:SAN;NYSE:SNY), Paris, France Ferring Pharmaceuticals A/S, Saint-Prex, Switzerland Business: Genitourinary Ferring reacquired rights to desmopressin acetate (dDAVP) from Sanofi to treat nocturnal …

    Published on 11/24/2014
  • Scynexis, Waterstone deal

    Scynexis Inc. (NASDAQ:SCYX), Research Triangle Park, N.C. Waterstone Pharmaceuticals Ltd., Wuhan, China Business: Infectious Scynexis granted Waterstone exclusive, worldwide rights to develop and commercialize SCY-635 …

    Published on 11/24/2014
  • sphingotec, GeneNews deal

    sphingotec GmbH, Hohen Neuendorf, Germany GeneNews Ltd. (TSX:GEN), Richmond Hill, Ontario Business: Diagnostic GeneNews received rights to sphingotecs breast cancer risk assessment assays, sphingotest pro-NT and …

    Published on 11/24/2014
  • Tekmira, Monsanto deal

    Tekmira Pharmaceuticals Corp. (TSX:TKM;NASDAQ:TKMR), Burnaby, Beta.C. Monsanto Co. (NYSE:MON), St. Louis, Mo. Business: Agbio/Environmental Tekmira received a $1.5 million milestone payment from Monsanto under a January…

    Published on 11/24/2014
  • Ubiquigent, University of Dundee deal

    Ubiquigent Ltd., Dundee, U.K. University of Dundee, Scotland, U.K. Business: Pharmaceuticals Ubiquigent partnered with the Drug Discovery Unit of the University of Dundee to develop and commercialize small molecule …

    Published on 11/24/2014
  • Valeant Pharmaceuticals, IGI deal

    Valeant Pharmaceuticals International Inc. (TSX:VRX;NYSE:VRX), Laval, Quebec IGI Laboratories Inc. (NYSE-M:IG), Buena, N.J. Business: Ophthalmic In September, IGI purchased two of Valeants ophthalmic products and …

    Published on 11/24/2014
  • Vectura deal

    Vectura Group plc (LSE:VEC), Chippenham, U.K. Business: Pulmonary Vectura received a $1.5 million milestone payment from an undisclosed pharma under a 2011 deal granting the pharma rights to develop and commercialize …

    Published on 11/24/2014
  • Zogenix, Purdue Pharma deal

    Zogenix Inc. (NASDAQ:ZGNX), San Diego, Calif. Purdue Pharma L.P., Stamford, Conn. Business: Neurology The companies exchanged waivers of regulatory exclusivity for their extended-release (ER) hydrocodone products, …

    Published on 11/24/2014
  • Alexza, Ferrer deal

    Alexza Pharmaceuticals Inc. (NASDAQ:ALXA), Mountain View, Calif. Grupo Ferrer Internacional S.A., Barcelona, Spain Business: Neurology The companies eliminated undisclosed milestone payments under a 2011 deal granting …

    Published on 11/17/2014
  • Aveo Pharmaceuticals, Ophthotech deal

    Aveo Pharmaceuticals Inc. (NASDAQ:AVEO), Cambridge, Mass. Ophthotech Corp. (NASDAQ:OPHT), New York, N.Y. Business: Ophthalmic Aveo granted Ophthotech an option to license exclusive ex-Asia development and …

    Published on 11/17/2014
  • BHV Pharma, Libbs deal

    BHV Pharma Inc., Research Triangle Park, N.C. Libbs Farmaceutica Ind., Sao Paulo, Brazil Business: Endocrine/Metabolic, Hepatic BHV granted Libbs exclusive rights in select Latin American countries, including Brazil, to…

    Published on 11/17/2014
  • Chembio, Integrated BioTherapeutics deal

    Chembio Diagnostics Inc. (NASDAQ:CEMI), Medford, N.Y. Integrated BioTherapeutics Inc., Gaithersburg, Md. Business: Diagnostic Chembio and Integrated BioTherapeutics partnered to develop point-of-care diagnostics for …

    Published on 11/17/2014

< Previous   1  2  3  4  5  6  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993